While reporting financial results for the third quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) raised its core adjusted earnings and revenue guidance for fiscal 2024.
For fiscal 2024, the company now projects core adjusted earnings in a range of $5.50 to $5.70 per share on revenues between $160 million to $165 million.
Previously, the company expected core adjusted earnings in the range of $5.00 to $5.50 per share on revenues between $140 million to $157 million.
On average, analysts polled by Thomson Reuters expect the company to report earnings of $5.39 per share on revenues of $156.38 million for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.